PuSH - Publikationsserver des Helmholtz Zentrums München

Nogueiras, R.* ; Rohner-Jeanrenaud, F.* ; Woods, S.C.* ; Tschöp, M.H.

The endocannabinoid system and the control of glucose homeostasis.

J. Neuroendocrinol. 20 Suppl 1, 147-151 (2008)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Blockade of the CB(1) receptor is one of the promising strategies for the treatment of obesity. The first selective CB(1) receptor antagonist, rimonabant, which has already successfully completed phase III clinical trials, led to sustained weight loss and a reduction in waist circumference. Patients treated with rimonabant also demonstrated statistically significant improvement in high-density lipoprotein cholesterol levels, triglyceride levels and insulin resistance, as well as a reduced overall prevalence of metabolic syndrome. Currently, one of the most discussed aspects of endocannabinoid system function is to what extent the endocannabinoid system might affect metabolism independently of its control over body weight and food intake. Specifically, a food-intake- and body-weight-independent role in the regulation of glucose homeostasis and insulin sensitivity could have major impact on the potential of drug candidates targeting the endocannabinoid system for the prevention and treatment of metabolic syndrome. This review summarises the effects of the endocannabinoid system on glucose homeostasis and insulin sensitivity.
Impact Factor
Scopus SNIP
Altmetric
0.900
0.900
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Sprache englisch
Veröffentlichungsjahr 2008
HGF-Berichtsjahr 2008
ISSN (print) / ISBN 0953-8194
e-ISSN 1365-2826
Quellenangaben Band: 20 Suppl 1, Heft: , Seiten: 147-151 Artikelnummer: , Supplement: ,
Verlag Blackwell
Verlagsort Oxford
Begutachtungsstatus Peer reviewed
PubMed ID 18426514
Erfassungsdatum 2020-02-24